Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis has hired Magnus Långberg as the new CFO of the Group; he will begin in January 2022.

Magnus Långberg has over 20 years of experience from a variety of positions within finance and management at international life science companies. He will be joining Genovis from his most recent position at Hemocue AB. Before that he worked at companies such as QPharma and BD Medical.

"I'm pleased to be able to welcome Magnus Långberg as the new CFO of Genovis. Magnus will have an important role in Genovis' continued development and I look forward to working with him," says Fredrik Olsson, CEO of Genovis.

Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.